Jurg Frei

Title: Jurg Frei: Innovator in Pharmaceutical Compounds

Introduction

Jurg Frei is a notable inventor based in Schonenbuch, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic compounds. His work has led to advancements in cardioselective beta-receptor blocking agents and stimulants.

Latest Patents

Jurg Frei holds a patent for 2-(3-Amino-2-hydroxy-propoxy)pyridine derivatives and pharmaceutical heterocyclic compounds. This patent includes valuable compounds of the formula wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl, or substituted pyridyl. The compounds are designed with specific functional groups, including R1 as hydrogen or methyl and R2 as lower alkyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl, or functionally modified carboxy-lower alkyl. These compounds are recognized for their potential as cardioselective beta-receptor blocking agents and stimulants.

Career Highlights

Jurg Frei has been associated with Ciba-Geigy Corporation, where he has utilized his expertise in pharmaceutical chemistry. His innovative approach has contributed to the development of new therapeutic agents that address cardiovascular conditions.

Collaborations

Throughout his career, Jurg Frei has collaborated with esteemed colleagues, including Knut A. Jaeggi and Franz Ostermayer. These collaborations have fostered a productive environment for research and development in the pharmaceutical sector.

Conclusion

Jurg Frei's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a key inventor. His work continues to influence the development of important therapeutic agents.